Expression vector of human GATA2.
Alternative name | SET-0121_4 |
---|---|
Clone info. | Expression vector of human GATA2. Expression has not yet been confirmed. |
Comment | cDNA fragment 338 to 1,777 of NM_032638.4 is cloned. PCR cloning, forward primer: gaggtggcgccggagcagcc; reverse primer: ctagcccatggcggtcaccatg. Known difference: C to G substitution at 349 nt (synonymous). |
Vector backbone | pCMV_S-FLAG (RDB05956) (Plasmid) |
Size of vector backbone | 5.5 kb |
Selectable markers | Amp^r (E. coli), Neo^r (mammalian cell) |
Growth conditions | 37C, LB+Amp |
Gene/insert name | Human GATA2 cDNA |
Depositor|Developer | DNA Bank, | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment ![]() ![]() ![]() MTA, for use for not-for-profit academic purpose [Word ![]() ![]() MTA, for use for for-profit purpose [Word ![]() Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL in any publication. Additional terms and conditions: Regrding pRc/CMV: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
必要書類 | 提供依頼書 ![]() ![]() 提供同意書 (MTA, 非営利学術目的用)[Word ![]() ![]() 提供同意書 (MTA, 営利目的用)[Word ![]() 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 発表に際し、理研BRCから入手したことを明記すること。 付加的使用条件: pRc/CMVについて: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
Catalog # | Resource name | Shipping form | Fee |
---|---|---|---|
RDB07004 | pCMFlag_hsGATA2 | DNA solution |
JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
Materials & Methods section:
The pCMFlag_hsGATA2 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07004). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB13716_A5L4p1.pdf ![]() |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: SV40pro_F Sequence file: RDB13716_A5L4a.seq ![]() |
---|
>07004_13716_A5L4_CMV-Forward_E09_15.ab1 1 CTTTAAACTT CCGCCCAATT GACGCAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA 61 TAAGCAGAGC TCTCTGGCTA ACTAGAGAAC CCACTGCTTA CTGGCTTATC GAAATTAATA 121 CGACTCACTA TAGGGAGACC CAAGCTGAAT TCACCATGGA CTACAAGGAC GATGACGATA 181 AGGCGGCCGA GGTGGCGCCG GAGCAGCCGC GCTGGATGGC GCACCCGGCC GTGCTGAATG 241 CGCAGCACCC CGACTCACAC CACCCGGGCC TGGCGCACAA CTACATGGAA CCCGCGCAGC 301 TGCTGCCTCC AGACGAGGTG GACGTCTTCT TCAATCACCT CGACTCGCAG GGCAACCCCT 361 ACTATGCCAA CCCCGCTCAC GCGCGGGCGC GCGTCTCCTA CAGCCCCGCG CACGCCCGCC 421 TGACCGGAGG CCAGATGTGC CGCCCACACT TGTTGCACAG CCCGGGTTTG CCCTGGCTGG 481 ACGGGGGCAA AGCAGCCCTC TCTGCCGCTG CGGCCCACCA CCACAACCCC TGGACCGTGA 541 GCCCCTTCTC CAAGACGCCA CTGCACCCCT CAGCTGCTGG AGGCCCTGGA GGCCCACTCT 601 CTGTGTACCC AGGGGCTGGG GGTGGGAGCG GGGGAGGCAG CGGGAGCTCA GTGGCCTCCC 661 TCACCCCTAC AGCAGCCCAC TCTGGCTCCC ACCTTTTCGG CTTCCCACCC ACGCCACCCA 721 AAGAAGTGTC TCCTGACCCT AGCACCACGG GGGCTGCGTC TCCAGCCTCA TCTTCCGCGG 781 GGGGTAGTGC AGCCCGAGGA GAGGACAAGG ACGGCGTCAA GTACCAGGTG TCACTGACGG 841 AGAGCATGAA GATGGAAAGT GGCAGTCCCC TGCGCCCAGG CCTAGCTACT ATGGGCACCC 901 AGCCTGCTAC ACACCACCCC CATCCCCACC TACCCCTCCT ATGTGCCGGC GGCTGCCCAC 961 GACTACAGCA GCGGACTCTT TCCACCCCGG GAGGCTTCCT GGGGGGGGAC CGGGCCTCCA 1021 GCTTTCACCC CCTAAGGCAG CGCAGCAAAG GCTCGTTTCC CTGTTTCAGA GGCCGGGAGG 1081 TTGTTGTTCA ACTGTGAGGC TACAGGCCAC CCTCTCTGGG CGGTGGGGAA CGGGCACCCA 1141 G // |
Primer: SV40 pro,Zeo,SV40p(A) Sequence file: RDB13716_A5L4b.seq ![]() |
>07004_13716_A5L4_BGHrev_F09_18.ab1 1 GAACGGGCAT TTTAGGGTGA ACTATAAGAA TAGGGCCCTC TAGATGCATG CTCGAGCGGC 61 CCTAGCCCAT GGCGGTCACC ATGCTGGACG GGTGGGGGTG GCCGAAGGAG AGGCTGGAGG 121 AGGGGTGGAT GGGCGTCGGA GTGGGCAGGA TGTGTCCGGA GTGGCTGAAG GGCGGGAGGT 181 GGCCCACAGG TGCCATGTGT CCAGCCAGGG CAGCTGCACT GAAGGGGGAT GACTTCTCCT 241 GCATGCACTT TGACAGCTCC TCGAAGCACT CCGCCCCTTT CTTGCTCTTC TTGGACTTGT 301 TGGACATCTT CCGGTTCCGA GTCTGGATCC CTTCCTTCTT CATGGTCAGT GGCCTGTTAA 361 CATTGTGCAG CTTGTAGTAG AGGCCACAGG CGTTGCAGAC AGGGTCCCCG TTGGCGTTTC 421 GGCGCCATAA GGTGGTGGTT GTCGTCTGAC AATTTGCACA ACAGGTGCCG GCTCTTCTGG 481 CGGCCGACAG TCTTCGCTTG GGCTTGATGA GTGGTCGGTT CTGCCCATTC ATCTTGTGGT 541 AGAGGCCACA GGCATTGCAC AGGTAGTGGC CGGTGCCGTC CCGCCGCCAG AGAGGGGTGG 601 CTGTGGCCCC ACAGTTGACA CACTCCCGGC CTTCTGAACA GGAACGAGCC TTGCTGCGCT 661 GCTTAGGGGT GAAGCTGGAG GCCGGTCCCC CCAGGAAGCC TCCGGGGTGG AAGAGTCCGC 721 TGCTGTAGTC GTGGGCAGCC GCCGGCACAT AGGAGGGGTA GGTGGGGATG GGGTGGTGT // |
Primer: SV40pro_F_V2 Sequence file: RDB13716_A5L4c.seq ![]() |
>07004_13716_A5L4_SV40pro_F_V2_G09_21.ab1 1 TCACAACTTT TTGGGAGGCC TAGGCTTTTG CAAAAGCTCC CGGGAGCTTG GATATCCATT 61 TTCGGATCTG ATCAAGAGAC AGGATGAGGA TCGTTTCGCA TGATTGAACA AGATGGATTG 121 CACGCAGGTT CTCCGGCCGC TTGGGTGGAG AGGCTATTCG GCTATGACTG GGCACAACAG 181 ACAATCGGCT GCTCTGATGC CGCCGTGTTC CGGCTGTCAG CGCAGGGGCG CCCGGTTCTT 241 TTTGTCAAGA CCGACCTGTC CGGTGCCCTG AATGAACTGC AGGACGAGGC AGCGCGGCTA 301 TCGTGGCTGG CCACGACGGG CGTTCCTTGC GCAGCTGTGC TCGACGTTGT CACTGAAGCG 361 GGAAGGGACT GGCTGCTATT GGGCGAAGTG CCGGGGCAGG ATCTCCTGTC ATCTCACCTT 421 GCTCCTGCCG AGAAAGTATC CATCATGGCT GATGCAATGC GGCGGCTGCA TACGCTTGAT 481 CCGGCTACCT GCCCATTCGA CCACCAAGCG AAACATCGCA TCGAGCGAGC ACGTACTCGG 541 ATGGAAGCCG GTCTTGTCGA TCAGGATGAT CTGGACGAAG AGCATCAGGG GCTCGCGCCA 601 GCCGAACTGT TCGCCAGGCT CAAGGCGCGC ATGCCCGACG GCGAGGATCT CGTCGTGACC 661 CATGGCGATG CCTGCTTGCC GAATATCATG GTGGAAAATG GCCGCTTTTC TGGATTCATC 721 GACTGTGGCC GGCTGGGTGT GGCGGACCGC TATCAGGACA TAGCGTTGGC TACCCGTGAT 781 ATTGCTGAAG AGCTTGGCGG CGAATGGGCT GACCGCTTCC TCGTGCTTTA CGGTATCGCC 841 GCTCCCGATT CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG ACGAGTTCTT CTGAGCGGGA 901 CTCTGGGGTT CGAAATGACC GACCAAGCGA CGCCCAACCT GCCATCACGA GATTTCGATT 961 CCACCGCCCG CCCTTCTATG AAGGGTTGGG GCTTTCGGAA ATCGTTTTTC CCGGGACGCC 1021 GGCTGGATGA TCCTCCAGCG CGGGGATCTC ATGCTGGAGT TCTTCGCCAA CCCCACTTGT 1081 TTATTGCAGC CTATATGCTA CCAATAAGGC ATTAGGCATC AACGAAATTT CACACA // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content